Florbetaben PET Imaging in Primary Progressive Aphasia
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Chicago
- Enrollment
- 1
- Locations
- 1
- Primary Endpoint
- Amyloid plaque levels in PPA participants
Study Overview
Brief Summary
The purpose of this research is to better understand how dementia affects activity in different parts of the brain.
Detailed Description
This study will examine Positron Emission Tomography (PET) imaging with Florbetaben F18. Florbetaben F18 is a radioactive tracer that binds to particles in your brain. This process displays activity in the brain. Florbetaben F18 is a PET amyloid imaging agent approved by the United States Food and Drug Administration (FDA) to estimate the amount of beta-amyloid plaque in adult patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The purpose of this research is to better understand how dementia affects activity in different parts of the brain. Currently, the scientific community is limited by how well it can see inside the brain. The use of a PET scan better helps us understand what the brain looks like in a diseased state. Participation in the study will help to understand what brain activity looks like, especially around language regions.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 100 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Participants must have a diagnosis of PPA or a related dementia syndrome
Exclusion Criteria
- •Breastfeeding
- •Receiving radiation clinically
Arms & Interventions
Experimental: Florbetaben F18 recipients
Participants in this arm of the study will receive 8.1mCi of florbetaben F18 and then be scanned in a PET scanner for brain imaging.
Intervention: Florbetaben F18 (Drug)
Experimental: Florbetaben F18 recipients
Participants in this arm of the study will receive 8.1mCi of florbetaben F18 and then be scanned in a PET scanner for brain imaging.
Intervention: PET (Device)
Outcomes
Primary Outcomes
Amyloid plaque levels in PPA participants
Time Frame: 2 Years
Amyloid plaque aggregation as measured by florbetaben F18 standard uptake value ratio cerebral and cerebellar regions of interest.
Secondary Outcomes
No secondary outcomes reported